More broadly, devising better approaches to fully block Ras pathway outputs such as through SHOC2 perturbation or combined pan-RAF (37) plus MEK inhibition may show benefit in depleting the subpopulation of MES-like tumor cells and improving clinical responses to targeted therapy, although further validation of SHOC2 across additional models will be critical. This evidence concerns the gene SHOC2 and neoplasm.